Grifols, S.A. has initiated the refinancing of its USD 6.3 billion debt which includes a loan used to finance its recent acquisition in the US, the Spanish firm. Grifols agreed in December to buy the shares it does not already own in a business for nucleic acid testing (NAT) donor screening from Hologic Inc. for USD 1.85 billion. In order to fund the transaction, the company announced that it would get a USD 1.7-billion term loan and cover the remainder with existing cash reserves.